The aim of this study was to examine the relationship between self-reported estrogen use and newly incident urinary incontinence (UI) among community-dwelling postmenopausal women.
The study was a population-based longitudinal survey of postmenopausal women who did not report UI in 1993 and for whom complete data were available. Women were classified as having newly incident UI if they reported uncontrolled urine loss within 12 months of the 2004 interview. Condition-specific functional loss secondary to UI was assessed using questions on the participants’ inability to engage in certain activities because of UI. The duration of hormone therapy containing estrogen was obtained in 1993 using a structured questionnaire.
Among the 167 postmenopausal women who did not report UI in 1993, 47 (28.1%) reported newly incident UI, and 31 (18.6%) reported newly incident UI with condition-specific functional loss in 2004. Of the 167 postmenopausal women, 46 (27.5%) reported using hormone therapy containing estrogen ever, and 14 (8.3%) women reported using hormone therapy containing estrogen for 5 years or more in 1993. Estrogen use for 5 years or more was significantly associated with newly incident UI with condition-specific functional loss compared with estrogen use for less than 5 years or having no reported history of estrogen (adjusted relative odds, 3.97; 95% CI, 1.02-15.43) in multivariate models controlling for potentially influential characteristics.
Postmenopausal community-dwelling women with a history of estrogen use for 5 years or more were more likely to report newly incident UI with condition-specific functional loss after 10 years of follow-up.
Results indicate that postmenopausal community-dwelling women with a history of estrogen use for 5 years or more were more likely to report newly incident urinary incontinence with condition-specific functional loss after 10 years of follow-up.
From the 1Department of Obstetrics and Gynecology, 2Department of Family Medicine and Community Health, and 3Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA.
Received April 22, 2011; revised and accepted June 30, 2011.
This study was presented at the American Urogynecologic Society Annual Scientific Meeting, Long Beach, CA, September 30–October 2, 2010.
Funding/support: This work was supported by Grant DA026652. Dr.Bogner was supported by Grants MH085880 and MH082799. Dr. Northington was supported by Grants 1P30AG031043-01 and K12-HD-000849-21.
Financial disclosure/conflicts of interest: None reported.
Address correspondence to: Hillary R. Bogner, MD, MSCE, Department of Family Medicine and Community Health, University of Pennsylvania School of Medicine, 3400 Spruce Street, 2 Gates Building, Philadelphia, PA 19104. E-mail: email@example.com